SALT LAKE CITY, November 19, 2025— With a deadline approaching on January 31, 2026, ARUP Laboratories has joined other clinical laboratories in advocating for passage of the federal Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, which would block looming cuts in payments for lab testing services, relieve labs of burdensome reporting, […]
The 2025 BioUtah Utah Life Sciences Summit (ULSS) took place November 12 at the Hilton Salt Lake City Center, featuring keynote speakers, awards, educational sessions, networking opportunities, and the signing of a Memorandum of Understanding (MOU) with the Korea Health Industry Development Institute. With 650 registrants, this year’s Summit was the biggest yet. Jefferson Moss, […]
IRVINE, Calif.–(BUSINESS WIRE)– Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement (“ASR”) to repurchase $500 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025. Under the terms of this ASR, Edwards will receive an initial delivery of approximately […]
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval. […]
As immigration enforcement and workplace inspections intensify under the current administration, companies in the life sciences sector, particularly those with manufacturing operations, must be proactive in strengthening compliance. Presented by Ogletree Deakin’s Kathleen Weron on July 1, 2025, this webinar provided an overview of the essential components of I-9 compliance, strategies for responding to audits, […]
BioUtah and its Utah consortium made their mark this week at the BIO International Conference, hosting a Utah Pavillion to promote the state’s fast-growing life sciences industry. The conference, held in Boston, MA. drew appproximately 20,000 attendees. The Utah delegation included BioUtah, Utah life sciences companies, the Governor’s Office of Economic Development, the Unversity of […]
SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical […]
More than a dozen Utah legislators on Wednesday, November 20, held a breakfast meeting of the Utah Life Sciences Innovation Caucus (ULSIC) at the state capitol. […]
BioUtah’s VP for Government Affairs, Denise Bell, along with a coalition of patient advocates, life sciences executives, pharmacists, physicians, oncologists, and community organizations, held a lunch meeting with Representatives Blake Moore (R-UT) and Celeste Maloy (R-UT) October 1 to discuss the dangers of giving pharmacy benefit managers (PBMs) command over how much patients pay for […]
Representatives John Curtis (R-UT) and Blake Moore (R-UT) toured bioMérieux. […]
Utah legislators on Wednesday, August 21, held a meeting of the Utah Life Sciences Innovation Caucus (ULSIC) at the state capitol. BioUtah President and CEO, Kelvyn Cullimore, introduced representatives from Salt Lake City-based bioMeriéux and Curza who presented before the ULSIC. Megan Kuehn, senior vice president of site operations for bioMeriéuxi, described the company’s development […]
ARUP maintains that the FDA’s rule will limit access to testing, stifle innovation, and increase healthcare costs. […]